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Keratoconus(KC) is an ecstatic corneal disease leading to corneal-thinning and the formation of a cone-like
cornea. Elevated lactate levels, increased oxidative stress, and myofibroblast formation have all been
previously reported. In the current study, we assess the role of Quercetin on collagen secretion and
myofibroblast formation in KC in vitro. Human corneal fibroblasts(HCFs) and human keratoconus
cells(HKCs) were treated with a stable Vitamin C derivative and cultured for 4 weeks, stimulating formation
of a self-assembled extracellularmatrix. All samples were analyzed usingWestern blots and targeted tandem
mass spectrometry. Our data showed that Quercetin significantly down regulates myofibroblast
differentiation and fibrotic markers, such as a-smooth muscle actin (a-SMA) and Collagen III (Col III), in
bothHCFs andHKCs. Collagen III secretion was reduced 80% in bothHCFs andHKCs followingQuercetin
treatment. Furthermore, Quercetin reduced lactate production by HKCs to normal HCF levels. Quercetin
down regulated TGF-bR2 and TGF-b2 expression in HKCs suggesting a significant link to the TGF-b
pathway. These results assert that Quercetin is a key regulator of fibrotic markers and ECM assembly by
modulating cellular metabolism and TGF-b signaling. Our study suggests that Quercetin is a potential
therapeutic for treatment of corneal dystrophies, such as KC.
A
ccording to the National Eye Institute, over 155,000 Americans are affected by Keratoconus (KC) with
20% of those reaching severe stages requiring corneal transplantation1. KC results in the formation of a
cone-like cornea and impaired vision due to compromised corneal integrity, degeneration of the basal
epithelial cells, and breakage of Bowman’s membrane2–4. Current treatments for mild to advanced KC patients
include rigid gas permeable lenses (RGPs) and corneal crosslinking5,6. These treatments serve to slow and, in some
cases, halt the progression of the disease by increasing collagen fibril linkages within the cornea, thereby pre-
venting extreme curvature. Corneal transplantation is currently the only available treatment for severe-stage KC
patients.
In the normal eye, the corneal stroma consists of the resident cells termed keratocytes and the assembled
extracellular matrix (ECM). The corneal stroma accounts for up to 90% of total corneal thickness and provide the
structural basis for the anterior segment of the eye7. Any disruptions in collagen architecture, collagenmechanical
properties, and collagen-linking enzyme activity can lead to altered ECM assembly and a defective corneal
structure, as observed in KC.
One of themain characteristics of KC is the significant loss of corneal ECM8,9. Unfortunately, to-date, there are
no treatments available to reverse or recover ECM loss and generate a more normal stroma-like cornea. A
fundamental hurdle in developing therapeutics to treat KC is largely due to the lack of a clear mechanism of
the molecular basis for the development and progression of this disease, as well as the absence of animal models.
Studies involving KC patients have focused on the analysis of tear and serum samples10–14, while the majority of
studies in vitro are utilizing 2D conventional cell culture models. We have previously developed a 3D in vitro
model15 showing that primary human keratoconus cells (HKCs) are terminally differentiated to myofibroblasts
and are unable to secrete comparable amounts of ECM relative to normal human corneal fibroblasts (HCFs)16.
We have also reported significant dysregulation of keymetabolites associated with glycolysis, citric acid cycle, and
oxidative stress in both 2D and 3DKC in vitro models17. Other studies have also associated KC withmutations in
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mitochondrial genes18, elevated mitochondrial damage19, increased
sensitivity to oxidative stress20,21, and increased apoptosis22.
Cellular metabolism is critical for maintaining homeostasis in the
tissue microenvironment by determining cytoplasmic functions
within the cell itself, as well as influencing the composition of the
extracellular niche. In the cornea, stromal keratocytes are dispersed
within the ECM and are directly affected by changes in metabolite
flux and ECM structure. Metabolite characterization has been used
by our group17 and others23,24 to investigate molecular characteristics
of disease, including KC. We have previously reported alterations in
the key metabolic pathway utilized by HKCs in primary energy pro-
duction favoring aerobic glycolysis and characterized by excess lact-
ate production17. Among other metabolites, lactate is a metabolite
known to be highly regulated both in HKCs17 and KC corneal but-
tons25. Lactate has also been implicated in corneal edema in vivo
promoting fibrosis during wound healing via activation of trans-
forming growth factor- b (TGF-b) signaling26,27. In this study we
examined the effect of a lactate transporter inhibitor, known as
Quercetin, on ECM assembly, fibrosis, and cellular metabolism in
KC.
Quercetin is a naturally produced flavonoid (Figure 1) that has
been reported to exhibit antifibrotic and antioxidant properties in
primary orbital fibroblasts and hepatocytes28–32. Several studies have
identified Quercetin as a potent inhibitor of monocarboxylate trans-
porter 1 (MCT1), which is a plasmamembrane transporter of lactate,
pyruvate, and ketone bodies33–35. MCT1 is ubiquitously expressed
throughout the body, including the cornea36. However, to the authors’
knowledge, there is no report of the effects of Quercetin on KC in
vitro or in vivo. The purpose of this study was to evaluate the effect of
Quercetin on HKCs using our 3D in vitro model15. In addition, we
examined the effects of Quercetin on cellular metabolism and fibrosis
using a variety of techniques to confirm our findings. Our results
show that Quercetin significantly decreases collagen secretion and
the expression of pro-fibrotic molecules via TGF-b signaling path-
way. Overall, we have identified Quercetin as a potential novel thera-
peutic to reduce scarring and attenuate oxidative stress regulatory
signals involved in the pathophysiology of KC.
Results
Lactate stimulation: Fibrotic effects. Lactate has been linked to
oxidative stress37,38 and cornea edema26. We have also previously
reported its link to KC disease in vitro17. Here, we tested the effects
of exogenous lactate stimulation at physiological pH within the
cornea on both HCFs and HKCs. Figure 2 shows regulation of Col
I (Figure 2A), Col III (Figure 2B), and a-SMA (Figure 2C) on HCFs
and HKCs at 0, 5, and 10mM lactate concentrations. Col I expression
was significantly up regulated in HCFs following 5 (Figure 2A; p ,
0.05) and 10 mM (Figure 2A; p, 0.05) lactate stimulation. However,
no significant difference was seen between 5 and 10 mM concen-
trations. Conversely, HKCs showed no significant up-regulation of
Col I upon lactate stimulation (Figure 2A). Col III expression was
significantly up-regulated in HCFs following lactate stimulation at
10 mM (100%; Figures 2B; p , 0.05). Interestingly, Control HKCs
showed approximately 125% higher expression of Col III when
Figure 1 | Chemical Structure of Quercetin (3,39,49,5,7-
Pentahydroxyflavone) generated using Chem Sketch.
Figure 2 | Quantification of western blots of HCF and HKC cell lysates following four week treatment with increasing concentrations of lactate.
(A) Col I expression was significantly up regulated (p, 0.05) inHCFs following 5 and 10 mMexogenous lactate stimulation, (B) Col III was significantly
up regulated (p, 0.05) in HCFs following 10 mM exogenous lactate stimulation. Col III expression was significantly higher at HKC-Control compared
to HCF-Control (p , 0.05), and (C) a-SMA was significantly up regulated in HCFs (p , 0.05) following 10 mM exogenous lactate stimulation. All
gels have been run under the same experimental conditions. n 5 3, error bars represent (SEM).
www.nature.com/scientificreports
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compared to HCFs (p, 0.05; Figure 2B), while there was almost a 2-
fold lower expression of Col III upon 10 mM lactate stimulation (p,
0.05; Figure 2B). Lactate stimulation had the biggest impact on Col III
expression in HKCs with a 100% reduction seen between HKCs
Control and HKCs at 10 mM lactate. a-SMA expression was only
modulated in HCFs upon 10 mM lactate stimulation, where a slight
but significant up regulation was noted (Figure 2C; p , 0.05) These
results support earlier published data17 that HKCs have a fibrotic
phenotype and suggest a potential role for excessive lactate produc-
tion in promoting scarring in fibrotic diseases.
Quercetin decreases collagen secretion into media. In order to
identify the effect of Quercetin on ECM secretion in HCFs and
HKCs, we quantified the Col III amounts released into the culture
media (Figure 3). We measured by Col III secretion (Figure 3) into
the culture media following incremental Quercetin concentrations
(0.1, 1, 2.5, 5, and 10mM). Figure 3 shows a linear decrease in Col III
expression in 20% increments by HCFs (Figure 3; p , 0.05). HKCs
showed elevated Col III expression at lowQuercetin doses (0–1mM; p
, 0.05) and reduced Col III levels (90%) at higher doses (5–10mM) of
Quercetin treatment (Figure 3; p , 0.05).
Col III levels were significantly higher in HKCs when compared to
HCFs at 1 and 2.5mMofQuercetin (Figure 3; p, 0.05). No toxicity of
Quercetin was observed in our in vitro model. Several studies39,40
have used similar concentrations up to 50–100mMQuercetin in vitro.
Quercetin stimulation: Anti-fibrotic effects. Since we identified
that Quercetin inhibited Col III secretion, we sought to investigate
if expression of Col III was inhibited independent of secretion and
reflective of general inhibition of myofibroblast differentiation. We
measured Col III and a-SMA expression in the presence and absence
of Quercetin (Figure 4). Figure 4 shows that 10mM Quercetin
treatment significantly inhibited expression of Col III (Figure 4A;
p , 0.05) and a-SMA (Figure 4B; p , 0.05) in the presence and
absence of lactate in both HCFs and HKCs. The reduction in Col III
and a-SMA expression following Quercetin treatment suggests that
Quercetin is a potential anti-fibrotic that may be useful in the
treatment of fibrotic diseases.
Quercetin alters metabolism in HCFs and HKCs. Since Quercetin
is a known inhibitor of the MCT1 lactate transporters33,41, we investi-
gated whether Quercetin can affect intracellular lactate production
in vitro by activating a negative feedback loop which would thereby
decrease secreted lactate concentrations. We used a metabolomics
analysis23,24 to identify variations in key metabolites in HCFs and
HKCs following Quercetin treatment.We observed significant changes
in specific metabolite concentrations, such as lactate and lactate-
derived metabolites (Figure 5). Figure 5A shows a 5-fold increase in
lactate production by untreated HKCs compared to HCFs. Quercetin
treatment caused a dramatic decrease in lactate production by HKCs
(Figure 5A; 2-fold, p, 0.03) and thereby restored lactate levels to the
normal HCF levels. Interestingly, identical regulation was seen with
two other key metabolites that are generated by phenylalanine and
lactate metabolism, atrolactate (Figure 5B) and phenyllactate (Figure 5C).
Figures 5B and 5C indicate that Quercetin did not cause a significant
increase of these two metabolites in HKCs compared to HCFs, which
showed a significant increase (2.5-fold, p, 0.05; and 2-fold, p, 0.05,
respectively). Our data suggest that Quercetin is directly inhibiting
the production of the excess lactate by HKCs rather than increasing
lactate-derived metabolites.
Quercetin: link to TGF-b pathway. Previous studies by us15,17 and
others25,42–45 have indicated a link between KC pathophysiology and
the TGF-b pathway. In order to determine if Quercetin inhibited
terminal myofibroblast differentiation in a TGF-b dependent manner,
we investigated changes in the TGF-b pathway. TGF-b2 and TGF-b
receptor II (TGF-bRII) levels were highly modulated. In HCFs, we
identified a substantial increase in TGF-bRII expression (Figure 6A;
4-fold; p, 0.05) following 10 mM lactate treatment but no change in
TGF-b2 (Figure 6B). HKCs on the other hand showed no significant
change in TGF-bRII expression (Figure 6A) but significantly up
regulated TGF-b2 (Figure 6B; p , 0.05). In agreement with our
Figure 3 | Quantification of Collagen III secretion into the culture media by HCFs and HKCs. (A) Representative western blots of Col III
regulation is shownwith increasing doses ofQuercetin (0, 0.1, 1, 2.5, 5, and 10mM). (B)Quantification of western blots for bothHCFs andHKCs is shown.
Quercetin stimulation of 10mM led to significant down regulation (p, 0.05) of Col III in HCFs media. HKCs showed higher Col III expression, when
compared to HCFs, at 1 and 2.5 mM of Quercetin. All gels have been run under the same experimental conditions. n 5 3, error bars represent SEM.
www.nature.com/scientificreports
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findings described above, Quercetin significantly decreased TGF-b2
and TGF-bRII expression in HCFs and HKCs even in the presence
of excess lactate (Figure 6A and 6B). This data overall indicated a
plausible link between elevated TGF-b activation and increased Col
III and a-SMA expression. These results suggest a possible role of
aberrant TGF-b signaling in altered ECM assembly by HKCs and the
potential use of Quercetin to attenuate pro-fibrotic signaling.
Discussion
KC is one of the most common corneal dystrophies that can lead to
severe visual impairment46. KC is characterized by a bilateral, non-
inflammatory progressive corneal ectasia that can lead to severe
visual impairment once severe stages are reached47,48. To date, there
is no therapeutic target available for the prevention of this disease,
and the pathogenesis of KC remains unknown. In addition, there is
Figure 4 | Quantification of western blots of HCF and HKC cell lysates following four week treatment with or without Quercetin and/or Lactate
treatment. (A) Col III expression was significantly down regulated (p , 0.05) in both HCFs and HKCs following 10mM Quercetin stimulation.
Lactate itself did not have a significant effect on Col III levels in either cell type, however combination of Lactate and Quercetin led to significant down
regulation of Col III (p , 0.05). (B) a-SMA expression followed similar pattern to Col III. It was significantly down regulated in both HCFs and
HKCs following 10mMQuercetin stimulation (p, 0.05) and in combination of Lactate and Quercetin. Lactate itself did not have a significant effect on
a-SMA levels in either cell type. All gels have been run under the same experimental conditions. n 5 3, error bars represent SEM.
Figure 5 | Quantified metabolomics data showing significant differences in lactate metabolite and lactate-derivatives: (A) Lactate metabolite showing
significant down regulation of expression in HKCs following Quercetin stimulation (p , 0.05), (B) Atrolactate showing significant up regulation
of expression in HCFs following Quercetin stimulation (p, 0.05), and (C) Phenyllactate showing significant up regulation (p, 0.05) of expression in
HCFs following Quercetin stimulation. n 5 3, error bars represent SEM.
www.nature.com/scientificreports
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no animal model available that can be used for studying the progres-
sion of the disease and promoting the development of novel treat-
ments. The aim of this study was to identify, describe, and characterize
the potential of Quercetin as a novel therapeutic to treat KC.
Quercetin is a common flavonol found in vegetables and fruits and
is abundant in human diets. Studies have investigated Quercetin as
an antioxidant39,49, anti-angiogenic50,51, neuroprotective52,53, and anti-
apoptotic agent54,55. In ocular studies, Quercetin has been found to be
efficacious in cataract prevention56, retinal angiogenesis57, and oxid-
ative damage in retinal pigment epithelium cells58,59. Surprisingly, the
number of published studies using Quercetin for corneal dystrophies
is lacking.
In this study, we have identified Quercetin as a potent inhibitor of
lactate-induced fibrosis in KC. Using a variety of established tech-
niques, we have shown that Quercetin attenuates collagen secretion
and terminal differentiation to the fibrotic phenotype observed in
HKCs. Considering its antioxidant properties, as previously reported
in the retina58,59, we hypothesized that Quercetin may target cellular
metabolism in both HCFs and HKCs. Our data is in agreement with
our previous observation17 that HKCs have altered cellular metabol-
ism, including elevated lactate production compared to HCFs. Further-
more, the results shown here suggest that Quercetin modulates fibrotic
signaling in HKCs by altering cellular metabolism and reducing lactate
production. Analogs of lactate, including atrolactate and phenyllactate,
which are primarily formed from lactate and phenylalanine metabol-
ism, increased significantly in HCFs following Quercetin treatment,
which suggests that Quercetin inhibits transport of any lactate pro-
duced by normal HCFs resulting in accumulation of cytoplasmic
lactate metabolites. The lack of increase in both atrolactate and
phenyllactate in HKCs suggests that Quercetin directly inhibits ele-
vated lactate production by these cells. It is therefore plausible to
postulate that the HKC phenotype may be corrected by altering
metabolism in order to promote a normal ECM assembly. This
hypothesis is supported by previous studies showing the potential
importance of metabolism in KC disease17,60.
The role of cellular metabolism in regulating corneal fibrosis is not
yet understood. Corneal fibrosis is a common feature associated with
the KC pathology and is also a major clinical problem with currently
only one treatment option: corneal transplantation. We have shown
evidence here that Quercetin is a potential novel inhibitor of anti-
fibrotic signaling and posit its potential for attenuating scar forma-
tion in KC and other diseases associated with fibrosis. As previously
reported by us, HKCs are terminally differentiated to myofibroblasts
with elevated a-SMA and Col III expression17. In the current study,
we advance our knowledge by linking key fibroticmarkers to elevated
lactate levels and demonstrate how these may be responsible for
promoting the HKC phenotype and altered cellular state. Based on
our findings, excess exogenous lactate can induce HCFs to undergo
terminal differentiation to a fibrotic phenotype similar to that observed
in HKCs with fibrotic characteristics.
While our long term aim is to identify and completely characterize
the cellular mechanisms in which HKCs are dysfunctional, we believe
Quercetin can play a major role in modulating the altered cellular
state to promote normality. Previous studies have identified varia-
tions in TGF-b signaling associated with KC25,42,44. We have shown in
this study that Quercetin down regulates expression of both TGF-
bRII and TGF-b2, which provides evidence of direct inhibition by
Quercetin of pro-fibrotic markers promoted by TGF-b signaling.
Figure 6 | Quantification of western blots of HCF and HKC cell lysates following four week treatment with or without Quercetin and/or Lactate
treatment. (A) TGF-bRII expression was significantly up regulated in HCFs following lactate stimulation (p , 0.05) and down regulated in HKCs
following Quercetin stimulation (p , 0.05), (B) TGF-b2 expression was significantly up regulated in HKCs following Lactate stimulation (p , 0.05)
whereHCFs showed no differences. Quercetin stimulation led to significant down regulation of TGF-b2 expression in bothHCFs andHKCs. All gels have
been run under the same experimental conditions. n 5 3, error bars represent SEM.
www.nature.com/scientificreports
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Collectively, our data show that Quercetin is a potent inhibitor of key
fibrotic markers and a strong metabolic regulator in KC and highlight
its potential as a therapeutic in the treatment of corneal scarring
associated with KC.
Methods
Cell isolation and treatment. Both HCFs and HKCs were prepared as previously
described15. HCFs were isolated from normal human corneas obtained from NDRI
(National Disease Research Interchange; Philadelphia, PA) and HKCs were isolated
from keratoconus corneas from Aarhus University Hospital, Aarhus, Denmark.
Briefly, corneal epithelium and endothelium were removed from the stroma by
scraping with a razor blade. The stromal tissue was cut into small pieces (23 2 mm)
and placed into flasks with Eagle’s Minimum Essential Medium (EMEM) with 10%
fetal bovine serum (Biologicals: Lawrenceville, GA). Explants were allowed to adhere
to the bottom of the plate. After 1–2weeks of cultivation, the cells were passaged into a
100 mm cell culture plate. Cells were grown to confluency and seeded at
concentrations of 106 cells per well in 6-transwell plates prior to treatment. Cells were
treated with Quercetin (3,39,49,5,7-pentahydroxyflavone) (Sigma Aldrich), lactic acid
(Sigma Aldrich), and 2-o-alpha-D-glucopyranosyl-L-ascorbic acid (American
Custom Chemicals Corporation). Quercetin was dissolved in DMSO. Less than 1%
v/v of solvent was added to cell culture media. All other reagents were dissolved in
ultrapure water unless otherwise stated. Controls were treated with vehicle. All
reagents were filter-sterilized with a 0.2micron filter prior to use in culture. Cells were
treated for 2 or 4 weeks with cell lysis at the respective time point. The research
adhered to the tenets of the Declaration of Helsinki.
Protein extraction andwestern blot.WeperformedWestern blot analysis from both
the culture media and the seeded cells. Protein extraction from media following
stimulation with lactate and/or Quercetin was pooled weekly by collecting the
supernatant from each well. Maximal volume of sample was loaded in each lane and
probed for Collagen I and III. For cell lysate protein extraction, lysates were extracted
in RIPA buffer (50 mM Tris, pH 8, 150 mM NaCl, 1% Triton X-100, 0.1% SDS, 1%
sodium deoxycholate) (Abcam; Cambridge, MA) supplemented with Complete Mini
protease and phosphatase inhibitors (Sigma Aldrich; St. Louis, MO). Briefly, cell
lysates were washed, lysed, centrifuged and stored at 220uC until further use. Total
protein concentration was quantified using the Pierce BCA Protein Assay
(Thermoscientific; Rockford, IL). Pre-cast sodium dodecyl sulfate (SDS)-
polyacrylamide (PAGE) gels (Life technologies; Grand Island, NY) were loaded with
25mg of total protein. SDS-Polyacrylamide gel electrophoresis was performed on cell
lysates under denaturing conditions. Western blot transfer was completed using
nitrocellulose (Abcam; Cambridge; MA), blocked in 5% bovine serum albumin in
TBST for 1 hour, and blots were probed overnight at 4uC in rabbit primary antibodies
in 1%BSA: anti-Collagen I (ab34710; Abcam; Cambridge;MA), Collagen III (ab7778;
Abcam; Cambridge; MA), Collagen V (ab94673; Abcam; Cambridge;MA), a-smooth
muscle actin (ab5694; Abcam; Cambridge; MA), glyceraldehyde 3-phosphate
dehydrogenase (GAPDH,ab9485; Abcam; Cambridge; MA) Secondary antibody
Goat anti-Rb Alexafluor 568 (Life technologies; Grand Island; NY) was incubated
with blot at room temperature for 1 hour with rocking. Quantification of bands was
performed with densitometry using OMEGA Carestream MI Standard Program. All
graphs depict Relative Expression (% Control) and error bars represent standard
error of the mean (SEM).
Metabolite extraction.Metabolites were isolated from cells as previously described17.
Briefly, cells were washed with 1xPBS and lysed with ice-cold 80% methanol,
incubated on dry ice for 15 minutes, and homogenized briefly to ensure complete cell
lysis. Samples were then centrifuged (14,000 g, overnight, 4uC) and metabolites were
isolated and stored at 280uC until use.
Mass spectrometry. Samples were re-suspended in 20 mL HPLC-graded water for
targeted tandem mass spectrometry (LC-MS/MS) and 5 mL were injected and
analyzed using a hybrid 5500 QTRAP triple quadrupole mass spectrometer (AB/
SCIEX) coupled to a Prominence UFLC system (Shimadzu) using an Amide HILIC
column (Waters) and analyzed with selected reaction monitoring (SRM) with
positive/negative polarity switching. Peak areas from the total ion current for each of
297 metabolite SRM transition were integrated using MultiQuant v2.1 software (AB/
SCIEX)23. The resulting raw data from the MultiQuant software was uploaded to
MetaboAnalyst (http://www.metaboanalyst.ca/MetaboAnalyst) for subsequent data
processing and analyses17,24
Statistical analysis. All experiments were repeated at least three times (separate
donors) and data was analyzed for significant variation (p , 0.05) using two-way
ANOVA and t-test where necessary (Graph Pad Prism 6 software).
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